Breaking: Dexcom Inc (NASDAQ:DXCM) Quarterly Sentiment Report

December 1, 2016 - By Hazel Jackson   ·   0 Comments

Breaking: Dexcom Inc (NASDAQ:DXCM) Quarterly Sentiment Report

Sentiment for Dexcom Inc (NASDAQ:DXCM)

Dexcom Inc (NASDAQ:DXCM) institutional sentiment decreased to 1.1 in Q2 2016. Its down -0.25, from 1.35 in 2016Q1. The ratio has worsened, as 144 institutional investors increased and opened new positions, while 107 sold and trimmed equity positions in Dexcom Inc. The institutional investors in our partner’s database now possess: 82.43 million shares, up from 78.09 million shares in 2016Q1. Also, the number of institutional investors holding Dexcom Inc in their top 10 positions decreased from 7 to 6 for a decrease of 1. Sold All: 30 Reduced: 77 Increased: 98 New Position: 46.

Dexcom, Inc. is a medical device company. The company has a market cap of $5.10 billion. The Firm is focused on the design, development and commercialization of continuous glucose monitoring systems for ambulatory use by people with diabetes and for use by healthcare providers for the treatment of people with and without diabetes. It currently has negative earnings. The Company’s products include SEVEN PLUS, DexCom G4, DexCom G4 PLATINUM, DexCom Share System and DexCom G5 Mobile.

About 231,606 shares traded hands. DexCom, Inc. (NASDAQ:DXCM) has declined 1.02% since April 28, 2016 and is downtrending. It has underperformed by 6.94% the S&P500.

Analysts await DexCom, Inc. (NASDAQ:DXCM) to report earnings on February, 28. They expect $-0.07 earnings per share, down 450.00% or $0.09 from last year’s $0.02 per share. After $-0.22 actual earnings per share reported by DexCom, Inc. for the previous quarter, Wall Street now forecasts -68.18% EPS growth.

According to Zacks Investment Research, “Dexcom Inc. is developing continuous glucose monitoring systems for people with diabetes.”

March Altus Capital Management Lp holds 7.17% of its portfolio in DexCom, Inc. for 11,700 shares. Shaker Investments Llc Oh owns 79,145 shares or 5.7% of their US portfolio. Moreover, Tirschwell & Loewy Inc has 3.77% invested in the company for 271,625 shares. The New York-based Bridger Management Llc has invested 3.63% in the stock. Sectoral Asset Management Inc, a Quebec – Canada-based fund reported 394,466 shares.#img1#

Insider Transactions: Since January 1, 0001, the stock had 0 buys, and 63 insider sales for $56.72 million net activity.

DexCom, Inc. (NASDAQ:DXCM) Ratings Coverage

Ratings analysis reveals 92% of Dexcom’s analysts are positive. Out of 12 Wall Street analysts rating Dexcom, 11 give it “Buy”, 0 “Sell” rating, while 1 recommend “Hold”. The lowest target is $70 while the high is $120. The stock’s average target of $90.88 is 44.39% above today’s ($62.94) share price. DXCM was included in 18 notes of analysts from August 6, 2015. As per Wednesday, February 24, the company rating was maintained by JP Morgan. Leerink Swann upgraded DexCom, Inc. (NASDAQ:DXCM) on Thursday, October 15 to “Outperform” rating. The firm earned “Buy” rating on Thursday, October 15 by Sterne Agee CRT. The firm has “Buy” rating given on Monday, October 31 by BTIG Research. Deutsche Bank maintained the shares of DXCM in a report on Friday, July 15 with “Buy” rating. JP Morgan maintained the shares of DXCM in a report on Thursday, September 17 with “Overweight” rating. Canaccord Genuity maintained it with “Buy” rating and $70 target price in Wednesday, November 2 report. Morgan Stanley initiated DexCom, Inc. (NASDAQ:DXCM) rating on Monday, November 2. Morgan Stanley has “Overweight” rating and $106 price target. The rating was maintained by Piper Jaffray with “Buy” on Friday, August 7. The stock of DexCom, Inc. (NASDAQ:DXCM) earned “Buy” rating by Jefferies on Wednesday, February 24.

DXCM Company Profile

Dexcom, Inc. (Dexcom), incorporated on May 13, 1999, is a medical device company. The Firm is focused on the design, development and commercialization of continuous glucose monitoring systems for ambulatory use by people with diabetes and for use by healthcare providers for the treatment of people with and without diabetes. The Company’s products consist of SEVEN PLUS, DexCom G4, DexCom G4 PLATINUM, DexCom Share System and DexCom G5 Mobile. The Firm had received Conformite Europeene Marking (CE Mark) approval for its fourth generation continuous glucose monitoring system, the DexCom G4 system, enabling commercialization of the DexCom G4 system in the European Union, Australia, New Zealand and the countries in Asia and Latin America.

More recent DexCom, Inc. (NASDAQ:DXCM) news were published by: Fool.com which released: “Here’s Why DexCom, Inc. Is Plunging Today” on November 02, 2016. Also Prnewswire.com published the news titled: “With Health Canada approval, Dexcom G5® Mobile CGM System is the First and …” on November 14, 2016. Prnewswire.com‘s news article titled: “Dexcom and Major League Soccer AT&T Rookie of the Year Jordan Morris Kick-off …” with publication date: November 10, 2016 was also an interesting one.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

By Hazel Jackson


Readers Comments (0)





Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our FREE daily email newsletter:


Recent Market News

>